Simon Pacey
University of Cambridge · 161 works · 6,757 citations · h-index 24
Top works
- Liquid biopsies come of age: towards implementation of circulating tumour DNA
- Phase I Pharmacokinetic and Pharmacodynamic Study of 17-Allylamino, 17-Demethoxygeldanamycin in Patients With Advanced Malignancies
- Enhanced detection of circulating tumor DNA by fragment size analysis
- Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer
- Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit.
- Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers
- A Phase I Study of the Heat Shock Protein 90 Inhibitor Alvespimycin (17-DMAG) Given Intravenously to Patients with Advanced Solid Tumors
- Economic evaluation of peripheral blood stem cell transplantation for lymphoma
- Hsp90 Inhibitors in the Clinic
- Acquired Resistance to 17-Allylamino-17-Demethoxygeldanamycin (17-AAG, Tanespimycin) in Glioblastoma Cells
- 382 Phase II antitumor activity of BAY 43-9006, a novel Raf kinase and VEGFR inhibitor, in patients with sarcoma enrolled in a randomized discontinuation study
- Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors
- A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma
- Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1–Deficient Thoracic Cancers
- Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RAS–RAF Mutations
- Use of Pharmacokinetic/Pharmacodynamic Biomarkers to Support Rational Cancer Drug Development
- Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial
- Characteristics, origin, and potential for cancer diagnostics of ultrashort plasma cell-free DNA
- Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of the Combination of Sorafenib and Tanespimycin
- Results of a phase 1 clinical trial investigating a combination of the oral mTOR-inhibitor Everolimus (E, RAD001) and Gemcitabine (GEM) in patients (pts) with advanced cancers